PriceTargets.com logo

Oramed Pharmaceuticals - ORMP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.60 As of 07/26/2024 01:00 AM ET
▲ +0.06 (2.36%)

This chart shows the closing price for ORMP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oramed Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORMP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Oramed Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.60.

This chart shows the closing price for ORMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Oramed Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2024HC WainwrightReiterated RatingNeutralLow
1/17/2023HC WainwrightDowngradeBuy ➝ NeutralLow
1/13/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
1/12/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$30.00 ➝ $3.00N/A
12/15/2022HC WainwrightReiterated RatingBuyLow
11/16/2022Alliance Global PartnersLower Target$35.00Low
3/17/2022HC WainwrightReiterated RatingBuy$32.00High
2/18/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00Low
11/29/2021HC WainwrightReiterated RatingBuy$17.00 ➝ $32.00High
11/9/2021Alliance Global PartnersBoost TargetBuy$25.00 ➝ $40.00Low
11/2/2021AegisBoost TargetBuy$20.00 ➝ $35.00High
6/8/2021AegisBoost TargetBuy$12.00 ➝ $20.00Low
4/27/2021Alliance Global PartnersBoost TargetBuy$11.00 ➝ $25.00Medium
2/15/2021AegisReiterated RatingBuyHigh
2/9/2021National SecuritiesInitiated CoverageBuyLow
1/27/2021AegisBoost TargetBuy$6.00 ➝ $12.00Low
12/3/2020Alliance Global PartnersInitiated CoverageBuy$11.00High
7/13/2020HC WainwrightReiterated RatingBuy$16.00 ➝ $17.00High
6/22/2020HC WainwrightReiterated RatingBuy$20.00 ➝ $16.00Medium
6/2/2020AegisReiterated RatingBuyLow
3/11/2020AegisInitiated CoverageBuy$5.50Medium
9/18/2019HC WainwrightSet TargetBuy$20.00Low
9/11/2019LADENBURG THALM/SH SHInitiated CoverageBuy$7.00 ➝ $7.00High
(Data available from 7/27/2019 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/27/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/27/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Oramed Pharmaceuticals logo
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Read More

Today's Range

Now: $2.60
Low: $2.55
High: $2.61

50 Day Range

MA: $2.39
Low: $2.07
High: $2.68

52 Week Range

Now: $2.60
Low: $1.67
High: $3.67

Volume

56,446 shs

Average Volume

148,481 shs

Market Capitalization

$105.64 million

P/E Ratio

10.00

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Oramed Pharmaceuticals?

The following sell-side analysts have issued research reports on Oramed Pharmaceuticals in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for ORMP.

What is the current price target for Oramed Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Oramed Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oramed Pharmaceuticals in the next year.
View the latest price targets for ORMP.

What is the current consensus analyst rating for Oramed Pharmaceuticals?

Oramed Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ORMP, but not buy more shares or sell existing shares.
View the latest ratings for ORMP.

What other companies compete with Oramed Pharmaceuticals?

Other companies that are similar to Oramed Pharmaceuticals include Entasis Therapeutics, Stealth BioTherapeutics, Cocrystal Pharma, Neoleukin Therapeutics and AC Immune. Learn More about companies similar to Oramed Pharmaceuticals.

How do I contact Oramed Pharmaceuticals' investor relations team?

Oramed Pharmaceuticals' physical mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company's listed phone number is (844) 967-2633 and its investor relations email address is [email protected]. The official website for Oramed Pharmaceuticals is www.oramed.com. Learn More about contacing Oramed Pharmaceuticals investor relations.